Introduction
Stroke is the third leading cause of death and the major cause of long-term disability in the United States (Lloyd-Jones et al., 2009 ). The only treatment currently approved by the FDA for acute stroke is recombinant tissue plasminogen activator (rtPA), a thrombolytic agent used to restore blood-flow interrupted by a blood clot (Weintraub, 2006) . However, response to rtPA therapy is time sensitive, and the drug must be administered within 6 hours post-infarct (Weintraub, 2006) . In addition to temporal limitations, the usage of rtPA is precluded by various factors, such as uncontrolled hypertension or patient use of anticoagulants, both of which can increase the risk of intracranial hemorrhaging caused by rtPA (Derex and Nighoghossian, 2008) . The lack in treatment options following ischemic stroke has driven the search for new stroke therapies.
Treatments that provide neuroprotection have also been explored in an effort to mitigate neuronal injury following ischemic stroke. The main area of research has been inhibition of Nmethyl-D-aspartate (NMDA) and (±)-α-Amino-3-hydroxy-5-methylisoxazole-4-propionic acid (AMPA) receptors. While some in vitro studies were promising, the in vivo results were less assuring. For example, Selfotel, a synthetic NMDA antagonist, showed significant improvements in an animal model of transient focal ischemia (Loscher et al., 1998) . However, Selfotel needed to be administered 1hr prior to the ischemic insult for best results, and showed no benefit if treatment was started >60 min post stroke (Madden et al., 1993) . Furthermore, clinical trials were terminated early due to adverse effects (Muir, 2006) .
One of the reasons for the failure of neuroprotective drugs that target a single ion channel is the fact that ischemic stroke is a complex syndrome. For example, after an ischemic insult, neurons switch from oxidative metabolism to anaerobic glycolysis, leading to the buildup of lactate within the cells and a reduction in tissue pH (Munoz Maniega et al., 2008) . This drop in tissue pH, along with synaptic proton release triggered in neurons by ischemia, activates the This article has not been copyedited and formatted. The final version may differ from this version. JPET Fast Forward. Published on October 12, 2012 as DOI: 10.1124 at ASPET Journals on July 12, 2017 jpet.aspetjournals.org
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J P E T # 1 9 9 5 1 3 6 acid sensing ion channel 1a (ASIC1a) (Xiong et al., 2004; Mari et al., 2010) . These channels contribute directly and indirectly to [Ca 2+ ] i dysregulation in neurons during ischemia (Herrera et al., 2008) , and are responsible for significant NMDA channel-independent brain injury following a stroke (Xiong et al., 2004) . In addition, activated microglia migrate to the site of insult and are part of the immune/inflammatory response that significantly contributes to stroke injury (Faustino et al., 2011) .
Sigma-1 (σ-1) receptors have been shown to be widely expressed in mammalian brain tissue (Cobos et al., 2008) and perform a number of functions, including regulation of plasma membrane ion channels and expression of antiapoptotic transcription factors (Zhang and Cuevas, 2002; Zhang and Cuevas, 2005; Zhang et al., 2009; Meunier and Hayashi, 2010) .
Activation of σ receptors was shown to regulate multiple Ca 2+ influx pathways known to be functionally upregulated during stroke, including ASIC1a (Katnik et al., 2006; Mari et al., 2010) .
In light of these findings and other reports in the literature, there has been much interest in exploring σ receptors as neuroprotective mediators during an ischemic stroke. One of the most exciting discoveries relating to σ receptors in stroke therapeutics is the potential of these receptors as viable targets for stroke therapy at delayed time points. Our group showed that activation of σ receptors using o-DTG reduced neuronal injury in an animal model of ischemic stroke even when the drug was administered 24 hr post-stroke (Ajmo et al., 2006) . guanidine substitutions were made in an attempt to characterize the structure-affinity relationships (Reddy et al., 1994; Schetz et al., 2007) 
MATERIALS AND METHODS

Preparation of Cortical Neurons:
All experiments were carried out on cultured cortical neurons from mixed sex embryonic day 18 (E18) Sprague-Dawley rats (Harlan, Indianapolis, IN). Methods used here were identical to those previously reported for the isolation and culturing of these cells (Katnik et al., 2006) .
Cortical neurons were used between 10-21 days in culture, which permits synaptic contact formation and yields the most robust responses to ischemia and acidosis. Animals were cared for in accordance with the regulations and guidelines set forth by the University of South Florida's College of Medicine Institution on Animal Care and Use Committee.
Calcium Imaging:
Intracellular Ca 2+ concentration was measured in isolated cortical neurons using ratiometric fluorometry as previously described (Katnik et al., 2006) . Cells plated on poly-Llysine coated coverslips were incubated at room temperature for 1 hr in B27 supplemented
Neurobasal medium (Invitrogen) containing 3 µg/ml of the acetoxymethylester form of fura-2 (fura-2 AM) in 0.3% DMSO. Prior to beginning the experiments, the coverslips were rinsed with physiological saline solution (PSS). For experiments in which cells were exposed to in vitro ischemia, the control PSS (PSS-1) consisted of (in mM): 140 NaCl, 3 KCl, 10 HEPES, 7.8 glucose, 2.5 CaCl 2 , and 1.2 MgCl 2 (pH to 7.2 with NaOH). The control PSS (PSS-2) for acidosis experiments contained (in mM): 140 NaCl, 4.5 KCl, 25 HEPES, 20 glucose, 1.3 CaCl 2 , and 1.0
MgCl 2 (pH to 7.4 with NaOH).
PSS was used as the control solution in all experiments. Solutions were delivered onto the cells via a rapid application system identical to that described previously (Cuevas and Berg, 1998) . In vitro ischemia was achieved using glucose-free PSS-1 containing 4 mM sodium azide (NaN 3 ) (Katnik et al., 2006) and acidosis was evoked via application of PSS-2 with a pH of 6.0 (Herrera et al., 2008) . Cells were only exposed to three or fewer episodes of ischemia or 
Microglial Migration:
The migration assays were carried out using a 48-well microchemotaxis chamber (Neuro Probe, Inc., Gaithersburg, MD) as described previously (Cuevas et al., 2011b) . The bottom wells of the chamber were filled with DMEM containing the chemoattractant, ATP (100 µM), and using Image-J in four random fields/well and the average for the fields used as the value for the well. For each experiment, a minimum of three wells were used, and the results of at least three experiments were averaged together.
Drugs and Chemicals:
The following drugs were used in this investigation: o-DTG and BD-1063 (Tocris Biosciences, Ellisville, MO); adenosine 5′-triphosphate disodium salt hydrate (Sigma-Aldrich, St. synthesized were subjected to verification via 13 C-, 1 H-NMR and mass spectrometry. Vehicles for drugs used were either dimethyl sulfoxide (DMSO) or ethanol (EtOH).
Data Analysis:
Fluorescence intensities were recorded from cortical neurons in the same manner as previously described (Katnik et al., 2006; Herrera et al., 2008) . Data were analyzed using Sigma Plot/Sigma Stat 11(Systat Software, Inc., San Jose, CA). Data points represent peak means ± standard error of the mean (S.E.M.). Paired and unpaired Student's t tests were used to determine significant differences within-and between-groups, respectively. Results were considered statistically significant if p < 0.05. One-and two-way analysis of variance were used for determining significant differences for multiple group comparisons, as appropriate, followed by post hoc analysis using either a Tukey or Dunn's test. Mean relative inhibitions were calculated using the following equation: Figure 5D ).
Experiments were also carried out to determine if the substitution of a bromo moiety could likewise affect the potency of the compounds. Figure 6A shows representative traces of with 10 nM BD-1063 ( Figure 9B ). Figure 9C ). BD-1063 alone had no effect on acidosis-induced [Ca 2+ ] i elevations ( Figure 9C ).
Recently, our laboratory showed that activation of σ receptors with pan-selective ligands such as o-DTG or afobazole modulates microglial activation, and inhibits microglial cell migration in response to chemoattractants such as ATP (Cuevas et al., 2011b) . This effect on microglial cell activation has been postulated to be a mechanism by which σ receptor activation reduces ischemic stroke injury (Cuevas et al., 2011b) . and 530 nM, respectively; whereas the affinity of DPhG for σ receptors is ~400 nM (Scherz et al., 1990; Reddy et al., 1994 (Scherz et al., 1990; Reddy et al., 1994) , and thus actions on that receptor cannot account for the discrepancy between σ receptor binding and functional effects. Since the earlier studies did not examine specifically σ receptor subtype binding affinity, the difference may be due to changes in affinity for one receptor subtype versus the other (i.e. σ-2 receptor affinity decreases significantly but σ-1 receptor affinity remains unchanged).
While migration and removal of the methyl moiety failed to alter functional properties of the molecule significantly, pronounced enhancement in potency were found with halide substitutions. Data presented here show that substituting a chloro for a methyl moiety in the meta and para positions of DTG produced compounds that had ~15% higher potency relative to the parent compound (o-DTG) at 100 μM concentration in the ischemia-induced increases in and 800 ± 57 nM affinities, respectively, with the σ-2 receptor affinity being significantly lower.
These values are similar to a previous report which indicates that p-BrDPhG binds guinea pig brain membrane extracts with an affinity of 540 ± 25 nM (Scherz et al., 1990) . That study also demonstrated that p-BrDPhG has lower binding affinity for the NMDA receptor than the parent compound (o-DTG), and therefore, the increased functional potency cannot be explained by increased action at the NMDA receptor. 2008), and thus effects by the σ-2 receptor were not tested in these assays.
The current study shows that p-BrDPhG also inhibits microglial activation and this DTG analogue is 4-fold more potent than the parent compound and a second pan-selective σ agonist, afobazole (Hall et al., 2009; Cuevas et al., 2011b) . Unlike ischemia-and acidosisevoked [Ca 2+ ] i dysregulation, which appears to be exclusively affected by σ-1 receptor activation, both σ-1 and σ-2 receptors can modulate microglial migration (Cuevas et al., 2011b) .
This observation may explain why p-BrDPhG, which has even lower affinity for σ-2 than σ-1, is only 4-fold more potent than o-DTG in the microglial migration assay but 8-to 34-fold more analogues suggested that the ortho position was the most tolerant to structural modifications, including addition of electronegative moiety (Scherz et al., 1990) . However, that report did not distinguish between σ-1 and σ-2 receptor binding, and thus the effects of those modifications on the respective receptors remains to be determined.
In conclusion, these findings show that the chloro and bromo substituted analogues of DTG have potential applications as anti-stroke therapeutics, showing a greater potency for inhibiting intracellular calcium dysregulation over o-DTG. In addition, p-BrDPhG blocks microglial migration with greater potency than o-DTG, indicating that this DTG analogue will both provide neuroprotection and mitigate the neuroinflammatory response known to contribute to stroke injury. Using identical in vitro screening methods, our group recently identified another, more potent, DTG analog, N,N'-(naphthal-oyl-1)-guanidine), that produces superior in vivo outcomes in a rat ischemic stroke model (Shahaduzzaman et al., 2012) . It is of significant interest to determine if the noted enhancement in potency of p-BrDPhG in vitro also translates into superior in vivo outcomes.
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